ContractSecond Registration Rights Agreement • June 27th, 2018 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York
This SECOND REGISTRATION RIGHTS AGREEMENT (as it may be amended from time to time in accordance with the terms hereof, the “Agreement”), dated as of June 25, 2018, is made by and among EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and EW Healthcare Partners L.P., EW Healthcare Partners-A L.P. and each other Person identified on the signature pages hereto as an “Investor” (together with their Permitted Transferees that become party hereto, the “Investors”).
COMMON STOCK PURCHASE WARRANT EYEPOINT PHARMACEUTICALS, INC.EyePoint Pharmaceuticals, Inc. • June 27th, 2018 • Laboratory analytical instruments
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Second Closing (the “Initial Exercise Date”) and on or prior to the close of business on the fifteenth (15th) Business Day following the date on which the Holder receives written notice from the Company that the Centers for Medicare & Medicaid Services has announced that a new C-Code has been established for DexycuTM and will be effective at the start of the first calendar quarter after such notice (the “Termination Date”), but not thereafter, to subscribe for and purchase from EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares of common stock, par value $0.001 per share (the “Common Shares”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common
